METTL1 and neoplasm: These findings suggest that Mettl1 inhibition may contribute to an immune microenvironment conducive to improved ICB therapy outcomes, highlighting the potential of targeting Mettl1 as a therapeutic strategy for enhancing the anti-tumour immune response.